[Full Pitch] Fraser Perring Of Viceroy Short This Company- 2018 Kase Learning Shortselling Conference

Full notes of Fraser Perring, Founder of Of Viceroy Research, from the 2018 Kase Learning Shortselling Conference.

Please note this transcript may contain mistakes - this was done by a human but its impossible to get every word correct and the audio was a bit unclear at times - enjoy

Q3 hedge fund letters, conference, scoops etc

…Research. One of three investment groups actually speaking, the joining us from London today. Fraser Perring, Gabriel, and Aidan are all at Viceroy which is perhaps best known for uncovering one of Europe’s largest frauds, Steinhoff, in the past year or so. We’re delighted to have you join us today.


It’s no secret huh. We are here today to present on Ebix. It’s something that came up over MiMedx basically. There were too many associations in the accounting practices and the regime that went with it through spending disclaimer.

Ebix Insurance Industry providing software, mainly to do with billing and then expanded out to the payment processing sector. The issues, red flags so to speak, came up in the acquisition. Some of them don’t make any sense whatsoever. They’ve had previous run-ins. I suspect that you have seen the report where <inaudible> 0:01:16.1 DOJ investigation that’s likely to be ongoing. It’s been previously announced and reported on by Gotham and Copperfield in terms of accounting irregularities, corporate governance issues, and mainly how they don’t benefit the shareholders. The segment data we came to in terms of the profit and loss and also how they recognize their revenues. It’s a really key thing. We were sued previously by MiMedx on similar issues that we raised.

So red flags. What are the red flags? They switched the storyline on how it’s going from insurance to the finance sector which has, shall we say, significantly high-risk jurisdiction. And you have Mauritius, Indonesia, some of the offices don’t exist and how they are pronounced is another story in the report. The bookkeeping has been reported on prior to 2014, how the irregularities stand out, and they are still there today, all the way up to the latest 10-Q with internal controls being the main issue. The auditors has been in six out of twelve years, mainly through Cherry Bekaert which was with MiMedx. The PCIOB found severe delinquencies, <inaudible> 0:02:49.6 there, we found that again in the present year.

They have a structure, I think the only way we can define it is absurd. This company is transferring ownership along the line of subsidiaries, from one to the other, then being dormant. That is not a red flag per se. The dormant companies have been wound up with all the assets.

And that leads me on to the CEO. The reason the court filing is a showing that the CEO is pretty much out to engineer some form of compensation program rules out any buyer. So any bold thesis is <inaudible> 0:03:33.2 in terms of how they are going to pay 825 million to the CEO, all signed up by all of them all in a copy and paste structure. You are sitting on a report that comes later in terms of the board, only copied and pasted, all in Robin Raina’s exact guidance, sign it off, endorsing it, and then gradually changing the controls within the company. This leads to some of the accounting practices that I hand over to Gobo to talk about.



This content is exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up here while also supporting quality content and journalism, or learn more about our premium content here

If you are subscribed and having an account error please clear cache and then cookies if that does not work email support@valuewalk.com and we will get back to you as quick as humanly possible

Saved Articles

The Life and Career of Charlie Munger

Charlie is more than just Warren Buffett’s friend and Berkshire Hathaway’s Vice Chairman – Buffett has actually credited him with redefining how he looks at investing. Now you can learn from Charlie firsthand via this incredible ebook and over a dozen other famous investor studies by signing up below:

  • Learn from the best and forever change your investing perspective
  • One incredible tidbit of knowledge after another in the page-turning masterpiece of a book
  • Discover the secrets to Charlie’s success and how to apply it to your investing
Never Miss A Story!
Subscribe to ValueWalk Newsletter. We respect your privacy.

Congrats! Are you a smart person?

We have an exclusive targeted & limited time offer for being a sophisticated and loyal reader.

ValueWalkPremium is a website and newsletter on the latest industry news much of which is not in the public domain and obtained via our sources.

We also have 10 years of resources on how to use this information to better your investment process.

Sign up for  today and get our exclusive content for 40% off. This is our second biggest discount ever!!

Use coupon code VIP20 or click on the button below

Limited time offer only ENDS 4/30/2020 or after the next 40 subscribers take advantage whichever comes first – please do not share this discount with others